Liminatus Pharma, Inc. Class A Common Stock (LIMN) — Financial statements
Income statement, balance sheet, and cash flow for Liminatus Pharma, Inc. Class A Common Stock — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.00↓100.0% | 3↓28.5% | 4↑102.8% | 2↓51.3% | 4 | |
| General & Administrative Expenses | 3↑360.1% | 0.65↓39.3% | 1↑24.1% | 0.86↑334.5% | 0.20 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 3↑360.1% | 0.65↓39.3% | 1↑24.1% | 0.86↑334.5% | 0.20 | |
| Other Expenses | 0.00↑100.0% | -0.42↑81.0% | -2 | 0.00↑100.0% | -1 | |
| Operating Expenses | 3↑2.1% | 3↑12.4% | 3↓4.5% | 3↑6.9% | 3 | |
| Total Costs & Expenses | 3↑2.1% | 3↑12.4% | 3↓4.5% | 3↑6.9% | 3 | |
| Operating Results | ||||||
| Operating Income | -3↓2.1% | -3↓12.4% | -3↑4.5% | -3↓6.9% | -3 | |
| Depreciation & Amortization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EBITDA | -10↓263.6% | -3↓152.2% | -1↑59.8% | -3↓162.0% | 4 | |
| EBIT | -10↓263.6% | -3↓152.2% | -1↑59.8% | -3↓162.0% | 4 | |
| Interest & Other Income | ||||||
| Net Interest Income | -0.14↓36085.5% | -0.00↑99.8% | -0.17↑24.7% | -0.22↓1400.3% | 0.02 | |
| Interest Income | 0.08↓44.4% | 0.14↑1277.2% | 0.01 | 0.00↓100.0% | 0.02 | |
| Interest Expense | 0.22↑56.3% | 0.14↓21.1% | 0.18↓20.1% | 0.22 | 0.00 | |
| Non-Operating Income | 7↑4517.9% | -0.16↑89.4% | -1 | 0.00↑100.0% | -7 | |
| Other Income / Expenses | -7↓34799.7% | 0.02↓98.5% | 1↑736.5% | -0.22↓103.2% | 7 | |
| Income Before Tax | -10↓253.7% | -3↓142.0% | -1↑59.3% | -3↓167.0% | 4 | |
| Income Tax Expense | 0.00↓100.0% | 0.02↓44.6% | 0.03 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -10↓251.4% | -3↓136.9% | -1↑58.1% | -3↓167.0% | 4 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -10↓251.4% | -3↓136.9% | -1↑58.1% | -3↓167.0% | 4 | |
| Bottom-Line Net Income | -10↓251.4% | -3↓136.9% | -1↑58.1% | -3↓167.0% | 4 | |
| EPS (Basic) | -0.43↓7.5% | -0.40↓166.7% | -0.15↓82.3% | -0.08↓163.3% | 0.13 | |
| EPS (Diluted) | -0.43↓7.5% | -0.40↓166.7% | -0.15↓82.3% | -0.08↓163.3% | 0.13 | |
| Weighted Average Shares | 24↑230.3% | 7↓10.2% | 8↓76.7% | 34↓0.2% | 35 | |
| Weighted Average Diluted Shares | 24↑230.3% | 7↓10.2% | 8↓76.7% | 34↓0.2% | 35 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.